Paper35907261
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease.
Yabut JM and 1 other. Endocr Rev, 2023. Cited by 151 papers, by iCite.
Cite this record
ConductScience Library. Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease. Papers, record 35907261. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35907261
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Non-alcoholic Fatty Liver Disease | Major topic |
| Diabetes Mellitus, Type 2 | Major topic |
| Humans | |
| Glucagon-Like Peptide 1 | |
| Obesity | |
| Inflammation | |
| Hypoglycemic Agents | |
| Glucagon-Like Peptide-1 Receptor Agonists |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 154321 | CIHR | Canada | PubMed |
Source PubMed
Cited by104
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 151 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42713454 | Glucagon-Like Peptide-1 Receptor Agonist Use Before and After Liver Transplant. | Gastroenterol Hepatol (N Y) | 2026 | https://conductscience.org/library/papers/42713454 | PubMed |
| 42697915 | Comment on: GLP-1 receptor agonists and male sexual health: translating cardiometabolic benefits into erectile outcomes. | Int J Impot Res | 2026 | https://conductscience.org/library/papers/42697915 | PubMed |
| 42588152 | The MASLD-Cardio-Oncology Triangle: Dietary Patterns, Metabolic Remodelling and Implications for Cancer Therapy Tolerance. | Nutrients | 2026 | https://conductscience.org/library/papers/42588152 | PubMed |
| 42538520 | The Pleiotropic Therapeutic Perspectives of GLP-1 and GIP Receptor Agonists in Spinal Cord Injury: A Narrative Review. | Mol Neurobiol | 2026 | https://conductscience.org/library/papers/42538520 | PubMed |
| 42416572 | Metabolic Dysfunction-Associated Steatotic Liver Disease as a Systemic Driver of Heart Failure With Preserved Ejection Fraction: Mechanistic Insights and Emerging Therapeutic Perspectives. | Rev Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42416572 | PubMed |
| 42367867 | Novel bile salt analogs reduce lipid accumulation in liver cells with potential to treat both metabolic dysfunction-associated steatotic liver disease and Clostridioides difficile infection. | bioRxiv | 2026 | https://conductscience.org/library/papers/42367867 | PubMed |
| 42366210 | Biologics for cardiovascular diseases: from bench to bedside. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42366210 | PubMed |
| 42352264 | Emerging Therapeutic Perspectives in Obese Patients with MASLD Leading to Compensated Advanced Chronic Liver Disease. | Biomolecules | 2026 | https://conductscience.org/library/papers/42352264 | PubMed |
| 42318205 | Effects of SGLT-2 inhibitors and GLP-1 receptor agonists on liver function in patients with non-alcoholic fatty liver disease and type 2 diabetes. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42318205 | PubMed |
| 42307179 | The evolving therapeutic landscape of gut-pancreatic peptide signalling in metabolic disorders: from mono- to multi-agonist therapies. | Biosci Rep | 2026 | https://conductscience.org/library/papers/42307179 | PubMed |
| 42292219 | Efficacy and safety of GLP-1 receptor agonists in patients with metabolic-associated fatty liver diseases: an umbrella review. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42292219 | PubMed |
| 42271434 | GLP-1 receptor agonists as multisystem therapies: from glycemic control to cardiorenal, neuroimmune, and metabolic disease. | Diabetol Metab Syndr | 2026 | https://conductscience.org/library/papers/42271434 | PubMed |
| 42241516 | Adipose Tissue Plasticity, Lipoprotein Metabolism, and Cardiovascular Risk: The Emerging Role of the GLP-1 Axis. | Circ Res | 2026 | https://conductscience.org/library/papers/42241516 | PubMed |
| 42222506 | Exendin-4 protects brain endothelial cell damage against hyperammonemic condition. | Biochem Biophys Rep | 2026 | https://conductscience.org/library/papers/42222506 | PubMed |
| 42206026 | Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages. | Front Immunol | 2026 | https://conductscience.org/library/papers/42206026 | PubMed |
| 42205663 | Semaglutide and Its Potential Hepatoprotective Effects Against Acute Drug-Induced Liver Injury. | Cureus | 2026 | https://conductscience.org/library/papers/42205663 | PubMed |
| 42201157 | Beyond Glycemic Control: Ocular Effects of Glucagon-like Peptide-1 Receptor Agonists. | Vision (Basel) | 2026 | https://conductscience.org/library/papers/42201157 | PubMed |
| 42171681 | GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: mechanistic networks and translational implications: a review. | J Endocrinol Invest | 2026 | https://conductscience.org/library/papers/42171681 | PubMed |
| 42117589 | Glucagon-Like Peptide-1 Receptor Agonist Use and Liver-Related Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes in the All of Us Research Program. | Am J Gastroenterol | 2026 | https://conductscience.org/library/papers/42117589 | PubMed |
| 42072734 | Emerging Insights into the Liver-Pancreas Axis: A Central Hub in the Pathogenesis of Diabetes and Metabolic Diseases. | Biomolecules | 2026 | https://conductscience.org/library/papers/42072734 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| GCG | 2641 | PubTator's text mining | https://conductscience.org/library/genes/2641 | NCBI Gene |
| GLP1R | 2740 | PubTator's text mining | https://conductscience.org/library/genes/2740 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35907261
GET https://conductscience.org/api/papers/v1/35907261/cited_by?page=2